Lambda Wins Award
 Read More

Learn more about our current studies.
Read more

Phase I, Bioavailability (BA) /
Bioequivalence (BE)


  • 194 beds including 12 Phase I beds with access to more than 640+ beds globally that can accommodate large panels, long institutionalization and mix population studies
  • Phase I (First-in-Human) with extensive monitoring and Bioavailability (BA), Bioequivalence (BE), Pharmacokinetics (PK), Pharmacodynamic (PD), Interaction studies (drug/drug, drug/alcohol),  Dose Escalation (SAD/MAD), Safety & Tolerability, Dose Ranging and Vaccine studies
  • Extensive experience with a variety of dosage forms including immediate release (IR), controlled release (CR) modified release (MR), extended release (ER),  solid oral, oral thin films (OTF), oral dispersible tablets (ODT), sublingual, suppositories, inhalers, injections, patches, suspensions and nasal spray
  • Experience in working with a broad variety of therapeutic areas including cardiovascular, infectious diseases, psychiatric, gynecological, endocrine, neurological, anti-inflammatory, anti-infective, analgesic, gastrointestinal, respiratory, urological, dermatological
  • Proximity to emergency facilities
  • State-of-the-art emergency and resuscitation equipment
  • Dedicated controlled access pharmacy with continuous temperature & humidity monitoring
  • License to import and secure storage of narcotics & controlled drug substances
  • Provide ECG’s & EEG’s, Pulmonary Function Testing (PFT), Cognitive Drug Testing (CDR), Gastroesophageal monitoring, cardiac monitoring, Radiology (X-rays, MRIs)
  • Clinical team comprised of medical doctors, registered nurses, technicians, and medical assistants

Website Designed by Clutch Marketing